Business
Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n \n \n \n Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n SAN DIEGO\n \n and\n \n CALGARY, AB\n \n \n ,\n \n \n May 8, 2024\n \n \n /CNW/ -- Oncolytics Biotech\n \n ®\n \n Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Dr.\n \n Matt Coffey\n \n , President and Chief Executive Officer, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference, which is taking place\n \n May 14-15, 2024\n \n at the InterContinental New York Barclay in\n \n New York, NY\n \n . Additional details on the fireside chat can be found below.\n \n \n \n \n \n \n Date:\n \n \n Wednesday, May 15, 2024\n \n \n \n Time:\n \n \n 10:30 a.m. ET\n \n \n \n Location:\n \n InterContinental New York Barclay Grand Ballroom I, 2\n \n nd\n \n Floor\n \n \n Webcast Link:\n \n Available by\n \n clicking here\n \n \n \n Company management will also be participating in one-on-one investor meetings at the conference. To schedule a meeting, contact your RBC representative or email\n \n [email protected]\n \n .\n \n \n A live webcast of the Company's presentation will also be available on the Investor Relations page of Oncolytics' website (\n \n LINK\n \n ) and will be archived until\n \n August 13, 2024\n \n .\n \n \n \n About Oncolytics Biotech Inc.\n \n \n \n Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning \"cold\" tumors \"hot\" -- through innate and adaptive immune responses to treat a variety of cancers.\n \n \n Pelareorep has demonstrated synergies with multiple approved oncology treat...